Aptus Pharma Limited (APPL): Aptus Pharma 52 Week High Streak: Second Straight Session Near Peak

Aptus Pharma 52 Week High Streak has now run for its second straight session, with the stock trading within 2% of its 52-week high and moving at Rs 353.4. The latest data shows a cumulative change of -0.04% across the streak, while also confirming that the pattern is price-led; it does not establish a company-specific catalyst for the repeated near-high trade.

As of 18 September 2026 at 10:18 AM IST, Aptus Pharma Limited (APPL) was trading at Rs 353.4 versus a previous close of Rs 346.5, after opening and printing the day’s high and low at the same level. Turnover stood at Rs 0.01 crore and market capitalisation at Rs 594.25 crore. For readers tracking Aptus Pharma Share Price, the repeated-high pattern is more useful than a one-day move because it shows that the stock has stayed close to its one-year peak across sessions rather than only briefly touching it once.

Aptus Pharma 52 Week High Streak: Consecutive High Analysis

Metric	Value
Current Price	Rs 353.4
Previous Close	Rs 346.5
Today's Move	+Rs 6.9 (+1.99%)
Open	Rs 353.4
High	Rs 353.4
Low	Rs 353.4
Turnover	Rs 0.01 crore
Market Capitalisation	Rs 594.25 crore

Aptus Pharma Limited (APPL) traded at Rs 353.4 versus the previous close of Rs 346.5, a rise of 1.99%. The stock opened at Rs 353.4, reached a high of Rs 353.4 and touched a low of Rs 353.4.

Aptus Pharma Share Price Today shows a firm intraday reading, with the stock at Rs 353.4, up Rs 6.9 or 1.99% from the previous close of Rs 346.5. The day opened at Rs 353.4, and the high and low were also Rs 353.4, which places the latest print at the top of the recorded range so far. That makes the current session important not because it establishes a fresh peak, but because it extends the broader near-high pattern that has kept Aptus Pharma Stock News in view.

The market capitalisation of Rs 594.25 crore places Aptus Pharma in the same general size band as several other names in the trading space cited below. Turnover was Rs 0.01 crore, which is a factual traded-value reading and should not be read as a separate explanation for the move. For investors following Aptus Pharma Share Price Update, the key point is that the stock is trading close to its 52-week high again, while today’s numbers provide the short-term price context around that streak.

What the Repeated 52-Week Highs Show

The repeated near-high pattern suggests that Aptus Pharma has stayed in the market’s spotlight across consecutive sessions, but the numbers alone do not explain why. The latest streak is a second straight session near the 52-week peak, and the cumulative move across that streak is -0.04%. That means the broader price path has been tight even as the stock has remained close to its yearly high. It is this combination, rather than a single-day print, that defines the Aptus Pharma 52 Week High Streak.

Another useful detail is the relationship between the latest high and the earlier one-year peak. The current price is near the 52-week high, yet the data set does not provide a separate higher reference point for a new record. So the safe reading is simple: Aptus Pharma has remained near its one-year high across back-to-back sessions, and the pattern is confirmed by the latest numbers. For search intent around Aptus Pharma Back to Back 52 Week Highs and Aptus Pharma New One Year High, the article should be read as a streak update, not as evidence of a fresh all-time or lifetime high.

Aptus Pharma Limited (APPL) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 594.25 crore
P/E Ratio	128.63x
P/B Ratio	17.67x
ROE	30.48%
ROCE	30.01%
EPS	Rs 2.69
Book Value Per Share	Rs 19.61
Dividend Yield	0%

Aptus Pharma Limited (APPL) fundamental metrics show P/E 128.63x, P/B 17.67x, ROE 30.48%, ROCE 30.01%. These figures provide context only and are not a buy or sell signal.

Aptus Pharma Limited has a market capitalisation of Rs 594.25 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 128.63x, P/B at 17.67x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 30.48% and ROCE of 30.01%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 2.69, book value per share of Rs 19.61, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 13.6x, median ROE of 4.09%, median ROCE of 6.09%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Trading
Industry	Trading
Benchmark Scope	same industry
Company P/E Ratio	128.63x
Benchmark Median P/E	13.6x
Benchmark Average P/E	85.72x
Benchmark P/E Range	0x to 9,230.13x
Company P/B Ratio	17.67x
Benchmark Median P/B	1.39x
Company ROE	30.48%
Benchmark Median ROE	4.09%
Company ROCE	30.01%
Benchmark Median ROCE	6.09%
Company Market Capitalisation	Rs 594.25 crore
Benchmark Median Market Cap	Rs 52.76 crore

Aptus Pharma Limited (APPL) is classified under sector: Trading and industry: Trading.

Aptus Pharma Limited (APPL) has a P/E ratio of 128.63x, which is above the benchmark median of 13.6x, a difference of +845.81%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Aptus Pharma Limited (APPL) has a ROE of 30.48%, which is above the benchmark median of 4.09%, a difference of +645.23%. Aptus Pharma Limited (APPL) has a ROCE of 30.01%, which is above the benchmark median of 6.09%, a difference of +392.78%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
SK Minerals & Additives Limite	SKM	592.54	32.7	7.03	60.13	32.3
Foce India Ltd.	FOCE	587.15	471.74	16.04	20.11	19.08
Bijoy Hans Ltd.	ARVAYA	584.43	0	10.23	3.93	5.74
Hardwyn India Ltd.	HARDWYN	620.2	52.2	1.46	2.9	4.3
Uniphos Enterprises Ltd.	UNIENTER	620.21	31.55	0.28	0.85	0.85

Aptus Pharma Limited (APPL) has a P/E ratio of 128.63x compared with the displayed peer median of 32.7x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 30.48% compares with a peer median of 3.93% across the companies shown in the table. ROCE stood at 30.01% versus the displayed peer median of 5.74%, providing a capital-efficiency comparison. Aptus Pharma Limited (APPL) has a market capitalisation of Rs 594.25 crore. Among the 5 peers shown, 2 have a larger market capitalisation.

Why Investors Are Watching Aptus Pharma

• The stock is in a second straight session near its 52-week high, which keeps Aptus Pharma 52 Week High Streak in focus.
• The cumulative change across the streak is -0.04%, showing that the price has stayed close to the yearly peak.
• The current price is Rs 353.4 versus a previous close of Rs 346.5, giving a clear day-to-day reference point.
• Valuation remains high versus the sector median, with a P/E of 128.63 and a P/B of 17.67.
• ROE of 30.48% and ROCE of 30.01% keep Aptus Pharma Fundamental Analysis relevant for follow-up reading.

About Aptus Pharma

Aptus Pharma Limited is listed on NSE and BSE under the symbol APPL and operates in the Trading sector and Trading industry. The company’s latest market capitalisation stands at Rs 594.25 crore, placing it in a compact market-cap range relative to the broader sector universe. The latest ratios show a premium valuation and strong return metrics, which are the main company-level reference points available for readers tracking Aptus Pharma Company News and Aptus Pharma Stock Performance.

For a stock that is trading close to its 52-week high across consecutive sessions, the relevant company backdrop is not just the price chart but also the valuation and profitability profile. Aptus Pharma’s P/E, P/B, ROE, ROCE, EPS and book value are all the figures that matter most in this snapshot, alongside the repeated near-high pattern.

Track Aptus Pharma on Univest

Follow Aptus Pharma on Univest for live price updates, company news and future 52-week high updates. This page is useful for readers who want a quick view of the Aptus Pharma Share Price, the streak pattern and the latest valuation context in one place.

Frequently Asked Questions

What does Aptus Pharma 52 Week High Streak mean?

Ans. It means Aptus Pharma has traded within 2% of its 52-week high for consecutive sessions. In this case, the streak has reached a second straight session, which keeps the stock near its one-year peak.

How many consecutive sessions has Aptus Pharma stayed near its 52-week high?

Ans. Aptus Pharma has stayed within 2% of its 52-week high for two consecutive sessions. The latest reading therefore qualifies as a second straight session in the Aptus Pharma 52 Week High Streak category.

What is the cumulative move across the streak?

Ans. The cumulative change across the current streak is -0.04%. That figure is the best way to read the pattern across multiple sessions, because it captures the overall move rather than only one intraday print.

Did Aptus Pharma set a new all-time high today?

Ans. No all-time high is stated here, and the latest numbers should be read only as a near-52-week-high event. The article does not convert the streak into an all-time or lifetime high claim.

What is Aptus Pharma trading at right now?

Ans. Aptus Pharma was trading at Rs 353.4 as of 18 September 2026 at 10:18 AM IST. That is Rs 6.9 or 1.99% above the previous close of Rs 346.5.

Is there a confirmed company-specific catalyst behind the streak?

Ans. No company-specific catalyst is confirmed by the latest numbers. The data confirms a repeated near-high price pattern, but it does not establish a direct reason for why the stock has stayed close to its yearly peak.

How does Aptus Pharma compare with sector valuations?

Ans. Aptus Pharma trades at 128.63 times earnings and 17.67 times book, which is well above the sector median P/E of 13.6 and P/B of 1.39. That makes it a premium-valued stock within the trading sector sample.

What should investors monitor next?

Ans. Investors can watch whether the stock continues to trade close to its 52-week high, how the next price reading compares with the previous close, and whether the valuation gap versus peers remains wide. Those are the most relevant follow-up points.

Track Aptus Pharma Limited (APPL) Share Price on Univest

Use Aptus Pharma Limited (APPL) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.